TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26591686

Group type: EXPERIMENTAL
Intervention: Yi Zhi Chan Tuina manipulation with vertical force of 9.31 N for 10 min
Number of subjects: 45

Group type: COMPARATOR
Intervention: Yi Zhi Chan Tuina manipulation with 2 min treatment time
Number of subjects: 45

Group type: COMPARATOR
Intervention: Yi Zhi Chan Tuina manipulation with light force
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Yi Zhi Chan Tuina manipulation with medium force
Number of subjects: 45

Group type: COMPARATOR
Intervention: Yi Zhi Chan Tuina manipulation with heavy force
Number of subjects: 45
Study: 23131063

Group type: EXPERIMENTAL
Intervention: Robotic catheter ablation (RNS)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Manual catheter ablation
Number of subjects: 258
Study: 21552645

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 18471515

Group type: EXPERIMENTAL
Intervention: IC41 vaccine (3 different dose groups)
Number of subjects: 60

Group type: COMPARATOR
Intervention: HCV peptides alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IC41 vaccine
Number of subjects: 60
Study: 16927534

Group type: EXPERIMENTAL
Intervention: Test formulation of lithium carbonate 300 mg
Number of subjects: 24
Study: 12782436

Group type: EXPERIMENTAL
Intervention: 10 mg morphine sulfate applied topically to the ulcer
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo (water for injection) applied topically to the ulcer
Number of subjects: 5
Study: 10947689

Group type: EXPERIMENTAL
Intervention: Intravenous epinephrine (15 microg)
Number of subjects: 8
Study: 8976314

Group type: EXPERIMENTAL
Intervention: Curl-up (CU) exercise
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Posterior pelvic tilt (PT) exercise
Number of subjects: 33
Study: 1832340

Group type: EXPERIMENTAL
Intervention: Yipanzhu decoction (YD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 40
Study: 6581064

Group type: EXPERIMENTAL
Intervention: Fenoterol powder (0.2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Fenoterol aerosol (0.2 mg)
Number of subjects: 10
Study: 3780693

Group type: EXPERIMENTAL
Intervention: Aspirin pretreatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Probenecid pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no pretreatment)
Number of subjects: 0
Study: 31094639

Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (BFR)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study: 29310718

Group type: EXPERIMENTAL
Intervention: Metacognitive therapy (MCT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Eye Movement Desensitisation Reprocessing (EMDR)
Number of subjects: 100
Study: 26613821

Group type: EXPERIMENTAL
Intervention: Educational program based on the PRECEDE model
Number of subjects: 48

Group type: COMPARATOR
Intervention: Routine interventions (Control)
Number of subjects: 48
Study: 24962478

Group type: EXPERIMENTAL
Intervention: VRAM perineal reconstruction (Group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Primary perineal wound closure (Group B)
Number of subjects: 60
Study: 22669347

Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl 2 μg/kg with IV and IM saline placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: IV morphine 0.1 mg/kg with nasal and IM placebo
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: IM morphine 0.1 mg/kg with nasal and IV placebo
Number of subjects: 171

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 171
Study: 20511615

Group type: EXPERIMENTAL
Intervention: Etanercept 25 mg twice weekly for 12 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18201659

Group type: EXPERIMENTAL
Intervention: Subacromial injection of corticosteroids, local anesthetic, and contrast dye from anterolateral, lateral, or posterior locations
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subacromial injection of corticosteroids, local anesthetic, and contrast dye
Number of subjects: 60
Study: 16025045

Group type: EXPERIMENTAL
Intervention: Injection immunotherapy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal steroid use
Number of subjects: 42
Study: 12844093

Group type: EXPERIMENTAL
Intervention: Percutaneous technique (group A)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional cutdown (group B)
Number of subjects: 30
Study: 10585359

Group type: EXPERIMENTAL
Intervention: Plasma cystatin C
Number of subjects: 30
Study: 8946098

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth guards (30% dry w/w chlorhexidine)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (no chlorhexidine)
Number of subjects: 11
Study: 2013139

Group type: EXPERIMENTAL
Intervention: Percutaneous balloon commissurotomy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surgical closed commissurotomy
Number of subjects: 40
Study: 6275811

Group type: EXPERIMENTAL
Intervention: Fluphenazine hydrochloride or decanoate
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Follow-up (mean interval, 3.5 years)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Original sample
Number of subjects: 28
Study: 30683426

Group type: EXPERIMENTAL
Intervention: Nanocurcumin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30304425

Group type: EXPERIMENTAL
Intervention: Immediate pushing (n=1200)
Number of subjects: 2414

Group type: COMPARATOR
Intervention: Delayed pushing (n=1204)
Number of subjects: 2414

Group type: EXPERIMENTAL
Intervention: Immediate pushing
Number of subjects: 2414

Group type: COMPARATOR
Intervention: Delayed pushing
Number of subjects: 2414
Study: 27410922

Group type: EXPERIMENTAL
Intervention: Olanzapine 10 mg orally daily on days 1 through 4
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 25269863

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural Raising Healthy Children intervention (12 sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No intervention (usual care)
Number of subjects: 100
Study: 22900785

Group type: EXPERIMENTAL
Intervention: Liposome bupivacaine (≤266 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Bupivacaine HCl (≤200 mg)
Number of subjects: 9
Study: 19887625

Group type: EXPERIMENTAL
Intervention: Baltimore Healthy Stores (BHS) intervention
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (comparison group of eight stores)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: BHS shelf label presence
Number of subjects: 84
Study: 17985974

Group type: EXPERIMENTAL
Intervention: Palliative wound care strategies (SPECIAL approach)
Number of subjects: 0
Study: 16234044

Group type: EXPERIMENTAL
Intervention: Nitazoxanide 500 mg (tablet) for patients aged 12 years or older, 200 mg (oral suspension) for patients aged 4-11 years, 100 mg (oral suspension) for patients aged 1-3 years, administered twice daily for 3 days.
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 11399693

Group type: EXPERIMENTAL
Intervention: Second pulmonary rehabilitation program (PRP2)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Third pulmonary rehabilitation program (PRP3)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Yearly hospitalizations and exacerbations
Number of subjects: 61

Group type: COMPARATOR
Intervention: Yearly exacerbations
Number of subjects: 61

Group type: COMPARATOR
Intervention: Health-related quality of life (HRQL)
Number of subjects: 61
Study: 9413466

Group type: COMPARATOR
Intervention: Danaparoid sodium (750 anti-Xa units once a day for 6 weeks)
Number of subjects: 9
Study: 7954760

Group type: EXPERIMENTAL
Intervention: Combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP) 1620 mg lysine acetylsalicylate (equivalent to 900 mg aspirin) combined with 10 mg metoclopramide
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Combined oral lysine acetylsalicylate and metoclopramide (LAS-MCP)
Number of subjects: 266
Study: 3653766

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 60 mg/m2 every 3 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) 400 mg/m2, 40 mg/m2, and 40 mg/m2 respectively every 4 weeks
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 mg/m2 plus doxorubicin 40 mg/m2 every 3 weeks (secondary treatment)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cisplatin (CDDP)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Combination of cyclophosphamide, doxorubicin, and cisplatin (CAP)
Number of subjects: 30
Study: 31390458

Group type: EXPERIMENTAL
Intervention: Individual psycho-educational counseling (2 sessions)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 44
Study: 27267974

Group type: EXPERIMENTAL
Intervention: Cold-water immersion (CWI)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Mid-exercise cooling by intermittent facial water spray (SPRAY)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 9
Study: 25885677

Group type: EXPERIMENTAL
Intervention: Oral prednisolone (40 mg daily for 5 days)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 436
Study: 22845184

Group type: EXPERIMENTAL
Intervention: Written plus oral information before colonoscopy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral information before colonoscopy
Number of subjects: 0
Study: 21266792

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA, 10 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Lynestrenol (LYN, 15 mg/day)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Norethisterone (NET, 15 mg/day)
Number of subjects: 82
Study: 19453719

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Termination of VPA treatment
Number of subjects: 46
Study: 16885729

Group type: EXPERIMENTAL
Intervention: Coblation tonsillectomy
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unipolar electrocautery tonsillectomy
Number of subjects: 48
Study: 14739892

Group type: EXPERIMENTAL
Intervention: Prompt L‐Pop (Strong pH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: One‐Up Bond F (Intermediate pH)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ScotchBond Multi‐Purpose (separate etchant and primer)
Number of subjects: 24
Study: 11777668

Group type: EXPERIMENTAL
Intervention: Buspirone and group therapy (12-week double-blind placebo-controlled trial)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (12-week double-blind placebo-controlled trial)
Number of subjects: 50
Study: 8988693

Group type: EXPERIMENTAL
Intervention: Rapid application of vacuum
Number of subjects: 47

Group type: COMPARATOR
Intervention: Stepwise application of vacuum
Number of subjects: 47
Study: 8424014

Group type: EXPERIMENTAL
Intervention: 1% lidocaine anesthesia (0.2 to 0.5 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no lidocaine)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1% lidocaine anesthesia
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 1% lidocaine anesthesia and Control group
Number of subjects: 100
Study: 3301232

Group type: EXPERIMENTAL
Intervention: 200 mg cimetidine
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 31427273

Group type: EXPERIMENTAL
Intervention: Inhibitory continuous theta‐burst repetitive transcranial magnetic stimulation (cTBS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation (control)
Number of subjects: 0
Study: 28741383

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet) adherence intervention
Number of subjects: 163

Group type: COMPARATOR
Intervention: Control group (no dietary intervention)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence
Number of subjects: 163
Study: 26414973

Group type: EXPERIMENTAL
Intervention: 6 mg melatonin before bedtime
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 25890276

Group type: EXPERIMENTAL
Intervention: FR trial (25% fluid intake)
Number of subjects: 11

Group type: COMPARATOR
Intervention: HYD trial (full fluid intake)
Number of subjects: 11
Study: 22846439

Group type: EXPERIMENTAL
Intervention: FRT patients
Number of subjects: 23

Group type: COMPARATOR
Intervention: Evening chronotypes
Number of subjects: 23
Study: 22087865

Group type: COMPARATOR
Intervention: Bortezomib alone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bortezomib plus rifampicin
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Bortezomib plus dexamethasone
Number of subjects: 25

Group type: COMPARATOR
Intervention: Bortezomib alone, Bortezomib plus rifampicin, Bortezomib plus dexamethasone
Number of subjects: 25
Study: 18071723

Group type: EXPERIMENTAL
Intervention: Computer-assisted navigation (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional instrumented (Group 1)
Number of subjects: 60
Study: 16828475

Group type: EXPERIMENTAL
Intervention: hCG injection 3-4 hours earlier (Group C)
Number of subjects: 72

Group type: COMPARATOR
Intervention: hCG injection at the same interval (Group B)
Number of subjects: 72

Group type: COMPARATOR
Intervention: hCG injection with >or=47% immature oocytes (Group A)
Number of subjects: 72
Study: 12752519

Group type: EXPERIMENTAL
Intervention: Myobloc (botulinum toxin type B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 10767716

Group type: EXPERIMENTAL
Intervention: p53 and P-glycoprotein expression
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: p53 and P-glycoprotein negative
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: tumour size, p53, and P-gp expression
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: overall survival
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: disease-free status
Number of subjects: 111
Study: 8581442

Group type: EXPERIMENTAL
Intervention: Cold therapy (50 degrees F) for THA patients
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Cold therapy (not specified for TKA)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control (70 degrees F) for THA patients
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control for TKA patients
Number of subjects: 74

Group type: COMPARATOR
Intervention: Cold therapy and Control for both THA and TKA patients
Number of subjects: 74
Study: 2478415

Group type: EXPERIMENTAL
Intervention: Local prostaglandin (PG) F2 alpha and systemic PG E2 application
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual surgical technique
Number of subjects: 71
Study: 790914

Group type: EXPERIMENTAL
Intervention: 15(R)‐15 methyl‐PGE2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prostaglandin E2
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Naturally occurring prostaglandins (PGA2, PGB1, PGB2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synthetic analogues of prostaglandin E2 (15‐methyl and 16,16‐dimethyl)
Number of subjects: 0
Study: 31731651

Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Calcifediol (25D3)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (both D3 and 25D3)
Number of subjects: 67
Study: 29136444

Group type: EXPERIMENTAL
Intervention: Intramedullary nail fixation (nail group; n=161)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Locking plate fixation (plate group; n=160)
Number of subjects: 321
Study: 25957058

Group type: EXPERIMENTAL
Intervention: Resistance exercise (EXE) for 6 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (CONT)
Number of subjects: 23
Study: 24364364

Group type: EXPERIMENTAL
Intervention: Harmony@Home intervention
Number of subjects: 461

Group type: COMPARATOR
Intervention: Attention control
Number of subjects: 461

Group type: COMPARATOR
Intervention: Third active intervention
Number of subjects: 461
Study: 22100194

Group type: EXPERIMENTAL
Intervention: Candesartan-based therapy
Number of subjects: 2049

Group type: COMPARATOR
Intervention: Non-ARB-based standard therapy
Number of subjects: 2049
Study: 19220756

Group type: EXPERIMENTAL
Intervention: R-137696 2 mg t.i.d. for 4 weeks
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 17224029

Group type: EXPERIMENTAL
Intervention: Fully rough implants (FR)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Partially rough implants (PR)
Number of subjects: 26
Study: 15222523

Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% hyperbaric bupivacaine + 20 mg of fentanyl (Group F)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 4 ml of 0.5% hyperbaric bupivacaine + 0.4 ml normal saline (Group S)
Number of subjects: 40
Study: 12667371

Group type: EXPERIMENTAL
Intervention: Hypothermia group (local mild hypothermia at 6 degrees C for 48 hours)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Routine group (dehydrant, antihypertensive agent, etc.)
Number of subjects: 40
Study: 9689720

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 20
Study: 8526196

Group type: COMPARATOR
Intervention: Folinic acid + fluorouracil (arm A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Folinic acid + fluorouracil + 4-epidoxorubicin (arm B)
Number of subjects: 71
Study: 1958119

Group type: EXPERIMENTAL
Intervention: Linsidomine (0.8 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Nitroglycerin (0.15 mg)
Number of subjects: 80
Study: 6786134

Group type: EXPERIMENTAL
Intervention: Etomidate used alone for induction
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Etomidate combined with fentanyl
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Etomidate (10-20 micrograms/kilogramme bodyweight/minute) combined with fentanyl and muscle relaxants
Number of subjects: 3
Study: 31093795

Group type: EXPERIMENTAL
Intervention: Submental intubation
Number of subjects: 32

Group type: COMPARATOR
Intervention: Elective tracheostomy
Number of subjects: 32
Study: 28704258

Group type: EXPERIMENTAL
Intervention: STAND‐SIT (alternating standing and sitting every 30 minutes)
Number of subjects: 25

Group type: COMPARATOR
Intervention: SIT (continuous sitting condition)
Number of subjects: 25
Study: 26109173

Group type: EXPERIMENTAL
Intervention: Active case finding (ACF) program including provider-initiated home visits of all new sputum smear positive TB patients.
Number of subjects: 0
Study: 23786619

Group type: EXPERIMENTAL
Intervention: Topical 2-hexyldecanol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 110
Study: 21281671

Group type: EXPERIMENTAL
Intervention: Physical activity program (duration: 9 months)
Number of subjects: 59
Study: 19815152

Group type: EXPERIMENTAL
Intervention: 400 mg of ibuprofen 1 hour before separator placement, 400 mg at 3 hours after placement, and 400 mg at 7 hours after placement (Group A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo at 1 hour before separator placement, 400 mg of ibuprofen at 3 hours and 7 hours after placement (Group B)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo at 1 hour, 3 hours, and 7 hours after separator placement (Group C)
Number of subjects: 0
Study: 16762579

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-Hib vaccine
Number of subjects: 200

Group type: COMPARATOR
Intervention: DTaP-IPV plus Hib vaccine
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 200
Study: 15265815

Group type: EXPERIMENTAL
Intervention: Counselling training for doctors in intervention centres
Number of subjects: 2460

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 2460
Study: 11500337

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial prophylaxis (gentamicin/colistin/vancomycin 2% in Orabase, every 6 h)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Topical antimicrobial prophylaxis
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group A (placebo)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group B (placebo)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Study group (topical prophylaxis)
Number of subjects: 226
Study: 10204257

Group type: EXPERIMENTAL
Intervention: Curosurf prophylaxis
Number of subjects: 28

Group type: COMPARATOR
Intervention: Rescue treatment
Number of subjects: 28
Study: 7855225

Group type: EXPERIMENTAL
Intervention: 0.8 mg nicotine
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.8 ml saline
Number of subjects: 12

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 12
Study: 2660902

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow transplantation
Number of subjects: 85

Group type: COMPARATOR
Intervention: Intensive sequential chemotherapy
Number of subjects: 85
Study: 30704700

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 μg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 0
Study: 28103612

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg per day)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Gefitinib (250 mg per day)
Number of subjects: 256
Study: 26556084

Group type: EXPERIMENTAL
Intervention: CCFES
Number of subjects: 60

Group type: COMPARATOR
Intervention: NMES
Number of subjects: 60
Study: 24043283

Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg, then 0.6 mg/kg for 4 more days)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study: 21953143

Group type: EXPERIMENTAL
Intervention: Treatment with Rituximab
Number of subjects: 163

Group type: COMPARATOR
Intervention: Active disease
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: MMP‐3
Number of subjects: 163
Study: 17884176

Group type: EXPERIMENTAL
Intervention: Mindfulness-based Cognitive Therapy (MBCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 0
Study: 16792244

Group type: EXPERIMENTAL
Intervention: NiTi springs
Number of subjects: 12

Group type: COMPARATOR
Intervention: Elastomeric chains
Number of subjects: 12
Study: 14606504

Group type: EXPERIMENTAL
Intervention: 20 microg teriparatide
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51